WASHINGTON, Feb 21 (Reuters) – AstraZeneca Plc said on Thursday it would appeal a jury ruling that it pay $215 million in damages, in an Alabama lawsuit related to drug pricing under the Medicaid health program for the needy.

A state jury ruled AstraZeneca should pay $40 million in compensatory damages and $175 million in punitive damages. The company was charged with reporting false pharmaceutical prices to Medicaid, the joint state-federal program that insures millions of individuals.

The case in the Circuit Court of Montgomery, Alabama, stemmed from a 2005 lawsuit filed by the Alabama Attorney General alleging AstraZeneca and dozens of other companies inflated prices to Medicaid.

The Anglo-Swedish drug company said it would appeal the case to the Alabama Supreme Court if a trial court did not reject the jury’s verdict that it said was based on “numerous errors” throughout the proceedings.

It will also file a motion that the punitive damages violate state law, which caps such damages at three times compensatory damages, according to AstraZeneca spokesman Tony Jewell. (Reporting by Kim Dixon; Editing by Braden Reddall, Richard Chang)

 



We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.


Professional and appropriate manner

My claim was handled in a very professional and appropriate manner. I was very pleased with my outcome and that the claim was resolved without having to go through a trial.

—Michael